ANI Pharmaceuticals, Inc. (ANIP)Â
NASDAQ
Market Cap
$1.23B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
539 of 950
Rank in Industry
31 of 57
Largest Insider Buys in Sector
ANIP Stock Price History Chart
ANIP Stock Performance
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Insider Activity of ANI Pharmaceuticals, Inc.
Over the last 12 months, insiders at ANI Pharmaceuticals, Inc. have bought $0 and sold $34.67M worth of ANI Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at ANI Pharmaceuticals, Inc. have bought $562,034 and sold $30.19M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $138,794 was made by Walsh Patrick D () on 2022‑03‑21.
List of Insider Buy and Sell Transactions, ANI Pharmaceuticals, Inc.
| 2025-01-13 | Sale | SR. VP, GENERAL COUNSEL & SEC. | 400 0.0019% | $53.92 | $21,568 | +5.74% | ||
| 2024-12-17 | Sale | SVP & CFO | 7,500 0.0358% | $55.79 | $418,425 | -2.20% | ||
| 2024-12-13 | Sale | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $56.24 | $14,060 | -2.31% | ||
| 2024-12-11 | Sale | SVP, CHIEF HR OFFICER | 1,000 0.0048% | $60.00 | $60,000 | -6.30% | ||
| 2024-11-26 | Sale | PRESIDENT & CEO | 33,481 0.1592% | $57.99 | $1.94M | -2.59% | ||
| 2024-11-15 | Sale | HEAD OF RARE DISEASE | 6,500 0.0304% | $57.70 | $375,050 | -0.22% | ||
| 2024-11-13 | Sale | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $61.36 | $15,340 | -5.48% | ||
| 2024-10-14 | Sale | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $57.19 | $14,298 | -2.62% | ||
| 2024-09-13 | Sale | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $56.82 | $14,205 | -2.15% | ||
| 2024-08-13 | Sale | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $59.62 | $14,905 | 0.00% | ||
| 2024-07-18 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 2,743 0.0132% | $62.00 | $170,066 | -4.69% | ||
| 2024-07-17 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 14,257 0.0682% | $63.16 | $900,472 | -7.15% | ||
| 2024-07-16 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 22,000 0.103% | $64.27 | $1.41M | -8.94% | ||
| 2024-07-15 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 11,000 0.0508% | $63.38 | $697,180 | 0.00% | ||
| 2024-07-12 | Sale | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $64.91 | $16,228 | 0.00% | ||
| 2024-07-01 | Sale | SVP - CORP. DEV. & STRATEGY | 20,000 0.0924% | $63.44 | $1.27M | 0.00% | ||
| 2024-06-21 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 20,000 0.0866% | $58.90 | $1.18M | -0.03% | ||
| 2024-06-20 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 11,447 0.0503% | $59.86 | $685,217 | -1.48% | ||
| 2024-06-18 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 10,607 0.0474% | $60.76 | $644,481 | -3.65% | ||
| 2024-06-17 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 7,946 0.0359% | $61.41 | $487,964 | -5.26% |
Insider Historical Profitability
12.79%
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 632620 3.0099% | $58.46 | 1 | 56 | +24.75% |
| Lalwani Nikhil | PRESIDENT & CEO | 370378 1.7622% | $58.46 | 1 | 6 | +31.46% |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | 193226 0.9193% | $58.46 | 1 | 10 | +29.72% |
| CAREY STEPHEN P. | SVP & CFO | 154468 0.7349% | $58.46 | 0 | 4 | |
| Marken James G. | SVP OPS & PROD DEV | 124492 0.5923% | $58.46 | 0 | 9 | |
| Gutwerg Ori | SVP, GENERICS | 77227 0.3674% | $58.46 | 0 | 2 | |
| Mutz Christopher | HEAD OF RARE DISEASE | 76777 0.3653% | $58.46 | 0 | 4 | |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | 55588 0.2645% | $58.46 | 0 | 14 | |
| Davis Krista | SVP, CHIEF HR OFFICER | 49059 0.2334% | $58.46 | 0 | 2 | |
| Pera Antonio R | director | 26627 0.1267% | $58.46 | 1 | 2 | <0.0001% |
| TANNENBAUM RENEE P | director | 18211 0.0866% | $58.46 | 0 | 1 | |
| MERIDIAN VENTURE PARTNERS II LP | 10 percent owner | 1819259 8.6558% | $58.46 | 0 | 18 | |
| MORGENSTERN VICTOR A | director | 455571 2.1675% | $58.46 | 2 | 0 | +243.13% |
| MARSHBANKS TRACY | director | 349934 1.6649% | $58.46 | 0 | 16 | |
| RAYNOR DANIEL | director | 289003 1.375% | $58.46 | 0 | 8 | |
| EDELMAN JOSEPH | 10 percent owner | 209100 0.9949% | $58.46 | 23 | 7 | <0.0001% |
| PRZYBYL ARTHUR | President and CEO | 202589 0.9639% | $58.46 | 2 | 10 | +64.77% |
| SIMES STEPHEN M | Vice Chairman, President & CEO | 202167 0.9619% | $58.46 | 4 | 1 | +6.23% |
| HOLUBOW FRED | director | 61259 0.2915% | $58.46 | 1 | 2 | |
| Schrepfer Robert W | SVP - New Bus Dev & Spec Sales | 55927 0.2661% | $58.46 | 0 | 5 | |
| Walsh Patrick D | 53388 0.254% | $58.46 | 4 | 0 | +15.33% | |
| SULLIVAN LOUIS W | director | 47898 0.2279% | $58.46 | 2 | 0 | |
| DONENBERG PHILIP B | Sr. VP of Finance, CFO & Secy | 44322 0.2109% | $58.46 | 8 | 0 | +32.33% |
| KJAER PETER | director | 34425 0.1638% | $58.46 | 2 | 0 | +3.25% |
| HAUGHEY THOMAS | director | 30202 0.1437% | $58.46 | 4 | 0 | <0.0001% |
| MANGANO ROSS J | director | 26914 0.1281% | $58.46 | 19 | 0 | +73.75% |
| Arnold Charlotte C. | Vice President and CFO | 21385 0.1017% | $58.46 | 0 | 1 | |
| ROSENOW EDWARD C III | director | 20540 0.0977% | $58.46 | 1 | 0 | |
| Thoma Jeanne | director | 17785 0.0846% | $58.46 | 1 | 0 | <0.0001% |
| NASH DAVID | director | 5236 0.0249% | $58.46 | 1 | 0 | <0.0001% |
| BELL STEVEN J | VP Research & Pre-Clinical Dev | 875 0.0042% | $58.46 | 0 | 9 | |
| LEHMAN LEAH M | VP, Product Development | 0 0% | $58.46 | 1 | 5 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| BlackRock | $174.99M | 12.08 | 2.53M | +0.26% | +$445,888.50 | <0.01 | |
| The Vanguard Group | $90.31M | 6.23 | 1.31M | +1.35% | +$1.21M | <0.01 | |
| Helm Capital Management LLC | $66.26M | 4.57 | 958,533 | -14.8% | -$11.51M | 1.96 | |
| Deep Track Capital Lp | $56.82M | 3.92 | 822,001 | +37% | +$15.35M | 0.26 | |
| Dimensional Fund Advisors | $42.11M | 2.91 | 609,173 | +2.95% | +$1.21M | 0.01 | |
| State Street | $39.74M | 2.74 | 574,838 | -2.97% | -$1.22M | <0.01 | |
| William Blair Investment Management | $33.89M | 2.34 | 490,265 | -0.06% | -$20,185.96 | 0.09 | |
| Ranger Investment Management L P | $27.8M | 1.92 | 402,204 | -7.46% | -$2.24M | 1.82 | |
| Global Alpha Capital Management Ltd. | $27.01M | 1.86 | 390,750 | -32.91% | -$13.25M | 2.01 | |
| Geode Capital Management | $23.46M | 1.62 | 339,364 | +2.94% | +$668,941.73 | <0.01 | |
| Invesco | $22.4M | 1.55 | 324,042 | +25.38% | +$4.53M | 0.01 | |
| Morgan Stanley | $17.44M | 1.2 | 252,260 | +8.76% | +$1.4M | <0.01 | |
| Nuveen | $17.02M | 1.17 | 246,156 | +54.53% | +$6M | 0.01 | |
| Ameriprise Financial | $16.82M | 1.16 | 243,274 | +2.91% | +$475,614.41 | 0.01 | |
| JPMorgan Chase | $16.05M | 1.11 | 232,190 | +3.65% | +$564,584.72 | <0.01 | |
| Macquarie Group | $14.79M | 1.02 | 213,899 | -7.03% | -$1.12M | 0.01 | |
| Kennedy Capital Management Inc | $14.52M | 1 | 210,026 | -8.27% | -$1.31M | 0.31 | |
| Charles Schwab | $13.58M | 0.94 | 196,483 | +33.62% | +$3.42M | <0.01 | |
| TSW (Thompson, Siegel & Walmsley LLC) | $13.32M | 0.92 | 192,757 | -9.47% | -$1.39M | 0.21 | |
| Loomis, Sayles & Company | $12.47M | 0.86 | 180,343 | -0.05% | -$5,945.13 | 0.02 | |
| Northern Trust | $11.29M | 0.78 | 163,346 | -2.25% | -$259,652.26 | <0.01 | |
| Tang Capital Management, LLC | $10.37M | 0.72 | 150,000 | New | +$10.37M | 0.04 | |
| Renaissance Technologies | $9.39M | 0.65 | 135,902 | +42.16% | +$2.79M | 0.02 | |
| Citadel Advisors LLC | $8.21M | 0.57 | 118,766 | -31.74% | -$3.82M | 0.01 | |
| BNY Mellon | $8.18M | 0.56 | 118,291 | -6.23% | -$543,361.81 | <0.01 | |
| Qube Research & Technologies | $8.12M | 0.56 | 117,526 | +12.75% | +$918,806.79 | 0.01 | |
| Brandywine Global Investment Management | $7.95M | 0.55 | 115,071 | -13.75% | -$1.27M | 0.06 | |
| Russell Investments Group Ltd | $7.37M | 0.51 | 106,675 | +2.92% | +$209,256.46 | 0.01 | |
| Sio Capital Management LLC | $6.04M | 0.42 | 87,354 | New | +$6.04M | 2.18 | |
| Assenagon Asset Management S.A. | $5.8M | 0.4 | 83,944 | +121.28% | +$3.18M | 0.01 | |
| Wedge Capital Management L L P Nc | $5.59M | 0.39 | 80,861 | +23.39% | +$1.06M | 0.09 | |
| Marathon Micro Partners LLC | $4.92M | 0.34 | 71,170 | +1.93% | +$93,325.50 | 1.18 | |
| Hillsdale Investment Management Inc. | $4.67M | 0.32 | 67,510 | -2.74% | -$131,346.99 | 0.37 | |
| Jane Street Capital | $4.66M | 0.32 | 67,353 | +373.75% | +$3.67M | <0.01 | |
| Goldman Sachs | $4.55M | 0.31 | 65,790 | +59.68% | +$1.7M | <0.01 | |
| Rice Hall James & Associates, LLC | $4.48M | 0.31 | 64,834 | -0.13% | -$5,945.18 | 0.26 | |
| Cubist Systematic Strategies | $3.85M | 0.27 | 55,683 | +65.02% | +$1.52M | 0.03 | |
| Great Lakes Advisors® | $3.51M | 0.24 | 50,722 | +5.12% | +$170,751.06 | 0.03 | |
| Susquehanna International Group | $3.49M | 0.24 | 50,521 | +328.29% | +$2.68M | <0.01 | |
| American Century Investments | $3.46M | 0.24 | 50,114 | +220.81% | +$2.38M | <0.01 | |
| ClariVest Asset Management LLC | $3.46M | 0.24 | 50,110 | -0.14% | -$4,908.23 | 0.36 | |
| Trexquant Investment LP | $3.26M | 0.23 | 47,147 | +65.52% | +$1.29M | 0.06 | |
| Oberweis Asset Management Inc | $3.01M | 0.21 | 43,500 | 0% | +$0 | 0.22 | |
| Legal & General | $2.89M | 0.2 | 41,855 | +0.48% | +$13,825.99 | <0.01 | |
| Wellington Management Company | $2.82M | 0.19 | 40,730 | +336.92% | +$2.17M | <0.0001 | |
| Algert Global LLC | $2.53M | 0.18 | 36,580 | +154.03% | +$1.53M | 0.1 | |
| Comerica | $2.53M | 0.18 | 36,663 | -0.52% | -$13,272.82 | 0.01 | |
| RhumbLine Advisers | $2.53M | 0.17 | 36,553 | -3.68% | -$96,504.72 | <0.01 | |
| Swiss National Bank | $2.23M | 0.15 | 32,300 | +7.67% | +$158,999.00 | <0.01 | |
| Lisanti Capital Growth Llc | $2.22M | 0.15 | 32,085 | New | +$2.22M | 0.54 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.